Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

221 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Obeticholic Acid and Fibrates in Primary Biliary Cholangitis: Comparative Effects in a Multicentric Observational Study.
Reig A, Álvarez-Navascués C, Vergara M, Gómez-Domínguez E, Gallego-Moya A, Pérez-Medrano IM, Fábrega E, Hernández-Guerra M, Berenguer M, Estevez P, Arencibia A, Morillas RM, Horta D, Albillos A, Casado M, De la Cruz G, Fernandez-Bonilla E, Molina E, Hijona L, Diago M, Fernández-Rodriguez CM, González-Santiago JM, Sala M, Gómez-Camarero J, Romero-Gomez M, Suárez F, Vargas V, Ferre-Aracil C, Andrade RJ, Chahri N, Parés A. Reig A, et al. Among authors: diago m. Am J Gastroenterol. 2021 Nov 1;116(11):2250-2257. doi: 10.14309/ajg.0000000000001343. Am J Gastroenterol. 2021. PMID: 34158466
Rationale and design of TeraViC-4 study: a phase III, randomized clinical trial to evaluate the effects of treatment duration with peginterferon alfa-2a (40-kDa) and ribavirin in naïve patients with chronic hepatitis C virus infection without early virological response at week 4.
Sánchez-Tapias JM, Crespo J, Diago M, Pérez R, Romero-Gómez M, Muñoz-Sánchez M. Sánchez-Tapias JM, et al. Among authors: diago m. Methods Find Exp Clin Pharmacol. 2002 Nov;24(9):579-84. Methods Find Exp Clin Pharmacol. 2002. PMID: 12616704 Clinical Trial.
Serum immunological profile in patients with chronic autoimmune cholestasis.
Romero-Gómez M, Wichmann I, Crespo J, Parés A, Rodrigo L, Alvarez A, Diago M, Pons-Romero F, Sanchez-Munoz D, Aguilar-Reina J, Andrade RJ, Salmeron J, Sánchez-Pobre P, Rebollo JM, Martin-Vivaldi R, Castellano-Megias V, Nuñez-Roldan A, Bruguera M; Spanish Group for the Study of Autoimmune Cholangitis. Romero-Gómez M, et al. Among authors: diago m. Am J Gastroenterol. 2004 Nov;99(11):2150-7. doi: 10.1111/j.1572-0241.2004.40416.x. Am J Gastroenterol. 2004. PMID: 15554996
Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients.
Romero-Gómez M, Del Mar Viloria M, Andrade RJ, Salmerón J, Diago M, Fernández-Rodríguez CM, Corpas R, Cruz M, Grande L, Vázquez L, Muñoz-De-Rueda P, López-Serrano P, Gila A, Gutiérrez ML, Pérez C, Ruiz-Extremera A, Suárez E, Castillo J. Romero-Gómez M, et al. Among authors: diago m. Gastroenterology. 2005 Mar;128(3):636-41. doi: 10.1053/j.gastro.2004.12.049. Gastroenterology. 2005. PMID: 15765399
HLA-C and KIR genes in hepatitis C virus infection.
Montes-Cano MA, Caro-Oleas JL, Romero-Gómez M, Diago M, Andrade R, Carmona I, Aguilar Reina J, Núñez-Roldán A, González-Escribano MF. Montes-Cano MA, et al. Among authors: diago m. Hum Immunol. 2005 Nov;66(11):1106-9. doi: 10.1016/j.humimm.2006.02.001. Epub 2006 Mar 9. Hum Immunol. 2005. PMID: 16571411
Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment.
Sánchez-Tapias JM, Diago M, Escartín P, Enríquez J, Romero-Gómez M, Bárcena R, Crespo J, Andrade R, Martínez-Bauer E, Pérez R, Testillano M, Planas R, Solá R, García-Bengoechea M, Garcia-Samaniego J, Muñoz-Sánchez M, Moreno-Otero R; TeraViC-4 Study Group. Sánchez-Tapias JM, et al. Among authors: diago m. Gastroenterology. 2006 Aug;131(2):451-60. doi: 10.1053/j.gastro.2006.05.016. Gastroenterology. 2006. PMID: 16890599 Clinical Trial.
Clinical trial: pharmacodynamics and pharmacokinetics of re-treatment with fixed-dose induction of peginterferon alpha-2a in hepatitis C virus genotype 1 true non-responder patients.
Diago M, Crespo J, Olveira A, Pérez R, Bárcena R, Sánchez-Tapias JM, Muñoz-Sánchez M, Romero-Gómez M. Diago M, et al. Aliment Pharmacol Ther. 2007 Oct 15;26(8):1131-8. doi: 10.1111/j.1365-2036.2007.03470.x. Aliment Pharmacol Ther. 2007. PMID: 17894655 Free article. Clinical Trial.
Optical analysis of computed tomography images of the liver predicts fibrosis stage and distribution in chronic hepatitis C.
Romero-Gómez M, Gómez-González E, Madrazo A, Vera-Valencia M, Rodrigo L, Pérez-Alvarez R, Pérez-López R, Castellano-Megias VM, Nevado-Santos M, Alcón JC, Solá R, Pérez-Moreno JM, Navarro JM, Andrade RJ, Salmerón J, Fernández-López M, Aznar R, Diago M. Romero-Gómez M, et al. Among authors: diago m. Hepatology. 2008 Mar;47(3):810-6. doi: 10.1002/hep.22112. Hepatology. 2008. PMID: 18098299
Treatment of insulin resistance with metformin in naïve genotype 1 chronic hepatitis C patients receiving peginterferon alfa-2a plus ribavirin.
Romero-Gómez M, Diago M, Andrade RJ, Calleja JL, Salmerón J, Fernández-Rodríguez CM, Solà R, García-Samaniego J, Herrerías JM, De la Mata M, Moreno-Otero R, Nuñez O, Olveira A, Durán S, Planas R; Spanish Treatment of Resistance to Insulin in Hepatitis C Genotype 1 Group. Romero-Gómez M, et al. Among authors: diago m. Hepatology. 2009 Dec;50(6):1702-8. doi: 10.1002/hep.23206. Hepatology. 2009. PMID: 19845037 Clinical Trial.
221 results